Journal of the International Association of Providers of AIDS Care (Sep 2017)

Persistence of Macrocytosis after Discontinuation of Zidovudine in HIV-Infected Patients

  • Inski Yu MD,
  • Richard N. Greenberg MD,
  • Timothy N. Crawford PhD,
  • Alice C. Thornton MD,
  • Thein Myint MBBS

DOI
https://doi.org/10.1177/2325957417702486
Journal volume & issue
Vol. 16

Abstract

Read online

The duration of macrocytosis after stopping zidovudine (ZDV) is unknown. Among 104 HIV-infected patients treated with ZDV for more than 1 year, 84 patients had macrocytosis at ZDV discontinuation. The median mean corpuscular volume (MCV) was 114.6 fL (range 100-128 fL). Patients were divided into 2 groups: those who did (resolved macrocytosis, n = 36) and did not (persistent macrocytosis, n = 48) normalize MCV at 3 to 6 months after ZDV discontinuation. Alcohol use ( P = .02), smoking ( P = .03), and lower (but within normal range) folic acid levels ( P = .05) were related to the persistence of macrocytosis. A persistence of macrocytosis was observed in 57% at 3 to 6 months, 38% at 1 year and 37% at 2 years after ZDV therapy had stopped. Duration of ZDV therapy did not have an effect on the persistence of macrocytosis ( P = .73). The median time for the MCV to normalize after stopping ZDV was 12.5 months.